Indications
INDICATION

IMDELLTRA® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

INDICATION

IMDELLTRA® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

NCCN

National Comprehensive
Cancer Network® (NCCN®)

Tarlatamab-dlle IS AN NCCN CATEGORY 1 PREFERRED SUBSEQUENT TREATMENT OPTION IN ES-SCLC1
Amgen Therapy Locator™
amgen-locator

You are leaving IMDELLTRA.com

You are now leaving IMDELLTRA.com and entering another Amgen website. Amgen is not adopting such content into this website.


Go back to IMDELLTRA.com Leave the website

You are leaving
IMDELLTRAhcp.com

You are now leaving IMDELLTRAhcp.com and entering another external website. Amgen is not responsible for the content of the third party website and is not adopting such content into this website.


Go back to IMDELLTRAhcp.com Leave the website

Page Not Found

The page you requested does not exist

Back to Home